Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (GB:0QOK)
LSE:0QOK
Roche Holding AG (0QOK) Share Price & Analysis
29 Followers
0QOK Stock Chart & Stats
Day’s RangeCHF0 - CHF0
52-Week RangeCHF212.30 - CHF286.40
Previous CloseCHF281.84
Volume114.82K
Average Volume (3M)275.50K
Market Cap
CHF231.69B
Enterprise ValueCHF253.40B
Total Cash (Recent Filing)CHF7.51B
Total Debt (Recent Filing)CHF25.39B
Price to Earnings (P/E)21.2
Beta0.39
Next Earnings
Jan 30, 2025EPS Estimate
CHF8.19Last Dividend Ex-Date
Mar 14, 2024Dividend Yield3.39%
Share Statistics
EPS (TTM)13.32
Shares Outstanding702,562,700
10 Day Avg. Volume54,796
30 Day Avg. Volume275,503
Standard Deviation0.05
R-Squared0.04
Alpha0.00008
Financial Highlights & Ratios
Price to Book (P/B)93.14
Price to Sales (P/S)2.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF269.60Price Target Upside-5.73% Downside
Rating ConsensusHold
Number of Analyst Covering12
Roche Holding AG News
![[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised](https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1096459574-750x406.jpg)
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive top-line phase 1 data for oral once-daily GLP-1R agonist CT-996 in people with obesity without diabetes, shows 6.1% placebo-adjusted weight loss.
Financial PerformanceThe shares are expected to continue to outperform due to substantial earnings upgrade potential driven mostly by established franchises.
Sales GrowthExcluding the CV19 headwind, group, pharma, and diagnostics sales grew at highly respectable rates of 7%, 7% and 8% respectively.
Bears Say
Financial PerformanceThe largest downside risks include Vabysmo and Phesgo delivering only the consensus forecasts and the group margin not expanding between 2023 and 2029.
ForecastsUpgrades to the consensus forecasts are unlikely right now.
TransparencyImportant baseline characteristics and PK/PD parameters are not disclosed, making cross-trial comparisons difficult.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
19.78% Mutual Funds
9.30% Other Institutional Investors
70.93% Public Companies and
Individual Investors
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest share price was CHF212.30 and its highest was CHF286.40 in the past 12 months.
What is Roche Holding AG’s market cap?
Currently, no data Available
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 30, 2025 which is in 184 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 25, 2024. The company reported CHF10.23 earnings per share for the quarter, beating the consensus estimate of CHF9.365 by CHF0.865.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of CHF9.6 which represents an annual dividend yield of 3.39%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is CHF8.19.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF10.23 in its last earnings report, beating expectations of CHF9.365. Following the earnings report the stock price went up 2.25%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in GB:0QOK
---
Roche Holding AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF269.60 (-5.73% Downside)
CHF269.60 (-5.73% Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.29%
12-Months-Change
Fundamentals
Return on Equity
38.68%
Trailing 12-Months
Asset Growth
13.03%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
---
0QOK Company Deck
---
0QOK Earnings Call
Q2 2024
0:00 / 0:00
---
0QOK Stock 12 Month Forecast
Average Price Target
CHF269.60
▼(-5.73% Downside)
Technical Analysis
Best Analysts Covering 0QOK
1 Year
1 Year Success Rate
25/39 ratings generated profit
1 Year Average Return
+4.83%
reiterated a sell rating 13 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 64.10% of your transactions generating a profit, with an average return of +4.83% per trade.
---